Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283325 | 0.98 | AGER (0.45) | AGERHRH3AVPR1BLMNAMAPK1 | |
| SCHEMBL1283060 | 0.91 | AGER (0.47) | AGERAVPR1BKDM4ESLC6A4 | |
| SCHEMBL1282841 | 0.89 | LTA4H (0.42) | AGERHRH3AVPR1BLMNAMAPK1 | |
| SCHEMBL1283315 | 0.88 | BACE1 (0.43) | AGERHRH3AVPR1BLMNAMAPK1 | |
| SCHEMBL1283298 | 0.88 | ESR1 (0.49) | AGERHRH3AVPR1BLMNAMAPK1 | |
| SCHEMBL1283851 | 0.87 | KDM4E (0.43) | AGERAVPR1BSMN1; SMN2KDM4E | |
| SCHEMBL1615422 | 0.86 | MCHR1 (0.47) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL1283955 | 0.85 | KDM4E (0.49) | AGERHRH3SMN1; SMN2KDM4E | |
| SCHEMBL1283478 | 0.85 | KDM4E (0.45) | HRH3AVPR1BSMN1; SMN2KDM4E | |
| SCHEMBL1283931 | 0.85 | AGER (0.43) | AGERAVPR1BSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885HRH3 1265/4885AVPR1B 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.